|Articles|February 10, 2016
Celgene Expands Relationship with Medidata in Enterprise Clinical Trial Technology
Advertisement
Global Biopharma Adds Medidata Clinical Cloud® to Enhance Its Clinical Trial Data Management Capabilities
NEW YORK, N.Y. – February 10, 2016 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Celgene Corporation has expanded its eight-year technology relationship with Medidata to add the Medidata Clinical Cloud ® as its enterprise technology platform for all clinical trials worldwide.
To drive therapeutic excellence in the interest of patients through a sustainable pipeline of cancer and inflammatory disease treatments, Celgene is utilizing Medidata’s unified technology platform to enhance capabilities in data management, study planning and design, trial operations, analytics and patient engagement.
“Celgene’s deep commitment to patients, disruptive science and disease-altering medical innovation is at the heart of their clinical development strategy and, more broadly, the success that they are having in driving medical advances in many of the world’s difficult-to-treat diseases,” said Tarek Sherif, Medidata’s chief executive officer. “We are in the early days of a renaissance in drug discovery, and Medidata’s Clinical Cloud is playing a critical role in helping to power the kind of innovation that will improve the lives of patients around the world.”
Primarily a Medidata Rave ® (electronic data capture, management and reporting) customer since 2008, Celgene will expand its use of the Medidata Clinical Cloud to include Medidata Designer ® (study and protocol design); Medidata Grants Manager ® (site budgeting and planning); Safety Gateway (safety reporting); Medidata CTMS ® (clinical trial management); Medidata SQM ( site quality management) and Medidata Patient Cloud ePRO (electronic patient-reported outcomes). Celgene is also leveraging one of Medidata’s turnkey clinical analytics offerings, Medidata Insights™ , which provides advanced metrics, visualizations and the most powerful set of industry data and benchmarks.
“Drug development is becoming more complex by the day, with researchers exploring vast genomes and proteomes increasing prospects to control or cure disease through precision medicine. Medidata is providing Celgene and a rapidly growing list of other global life sciences companies with an integrated platform and the fundamental analytics and tools needed to optimize drug development programs,” said Glen de Vries, Medidata’s president. “We are thrilled to deepen our relationship with Celgene, a company that shares our passion for pushing the frontiers of science and technology and improving global health.”
About Medidata
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5